HRP20170471T1 - Spojevi piperazin-piperidina kao inhibitori hepatitis c virusa - Google Patents
Spojevi piperazin-piperidina kao inhibitori hepatitis c virusa Download PDFInfo
- Publication number
- HRP20170471T1 HRP20170471T1 HRP20170471TT HRP20170471T HRP20170471T1 HR P20170471 T1 HRP20170471 T1 HR P20170471T1 HR P20170471T T HRP20170471T T HR P20170471TT HR P20170471 T HRP20170471 T HR P20170471T HR P20170471 T1 HRP20170471 T1 HR P20170471T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- optionally substituted
- hydrogen
- compound
- 3alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637959P | 2012-04-25 | 2012-04-25 | |
| US201361774033P | 2013-03-07 | 2013-03-07 | |
| PCT/US2013/037920 WO2013163262A1 (en) | 2012-04-25 | 2013-04-24 | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
| EP13720201.6A EP2850075B1 (en) | 2012-04-25 | 2013-04-24 | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170471T1 true HRP20170471T1 (hr) | 2017-06-02 |
Family
ID=48237291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170471TT HRP20170471T1 (hr) | 2012-04-25 | 2013-04-24 | Spojevi piperazin-piperidina kao inhibitori hepatitis c virusa |
Country Status (17)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CN112480084B (zh) * | 2017-11-27 | 2021-09-21 | 常州寅盛药业有限公司 | 反应路线简单的达卡他韦起始原料的合成方法 |
| EP4759807A1 (en) | 2023-08-11 | 2026-06-17 | Shenzhen Zhongge Biological Technology Co., Ltd. | Proteolysis targeting chimera compound for degrading irak4 and use thereof |
| CN122497677A (zh) | 2023-10-20 | 2026-07-31 | 奇树医药公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG176015A1 (en) | 2009-05-13 | 2011-12-29 | Gilead Sciences Inc | Antiviral compounds |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| EP2475254A4 (en) * | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102883718A (zh) | 2009-12-24 | 2013-01-16 | 顶点制药公司 | 用于治疗或预防黄病毒感染的类似物 |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| MA34147B1 (fr) | 2010-03-09 | 2013-04-03 | Merck Sharp & Dohme | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CA2814534A1 (en) | 2010-11-04 | 2012-05-10 | Theravance, Inc. | Novel inhibitors of hepatitis c virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR088630A1 (es) | 2011-11-03 | 2014-06-25 | Theravance Inc | Inhibidores del virus de la hepatitis c |
| CA2869908C (en) * | 2012-04-25 | 2018-02-20 | Theravance Biopharma R&D Ip, Llc | Hepatitis c virus inhibitors |
-
2013
- 2013-04-24 LT LTEP13720201.6T patent/LT2850075T/lt unknown
- 2013-04-24 JP JP2015509099A patent/JP6069491B2/ja not_active Expired - Fee Related
- 2013-04-24 US US13/869,199 patent/US9206159B2/en not_active Expired - Fee Related
- 2013-04-24 WO PCT/US2013/037920 patent/WO2013163262A1/en not_active Ceased
- 2013-04-24 ES ES13720201.6T patent/ES2624846T3/es active Active
- 2013-04-24 SI SI201330640A patent/SI2850075T1/sl unknown
- 2013-04-24 DK DK13720201.6T patent/DK2850075T3/en active
- 2013-04-24 RS RS20170354A patent/RS55864B1/sr unknown
- 2013-04-24 HR HRP20170471TT patent/HRP20170471T1/hr unknown
- 2013-04-24 HU HUE13720201A patent/HUE032173T2/en unknown
- 2013-04-24 PL PL13720201T patent/PL2850075T3/pl unknown
- 2013-04-24 EP EP13720201.6A patent/EP2850075B1/en active Active
- 2013-04-24 CA CA2869640A patent/CA2869640C/en not_active Expired - Fee Related
- 2013-04-24 PT PT137202016T patent/PT2850075T/pt unknown
- 2013-04-24 ME MEP-2017-85A patent/ME02682B/me unknown
- 2013-04-24 CN CN201380021717.8A patent/CN104302639B/zh not_active Expired - Fee Related
-
2017
- 2017-05-17 CY CY20171100520T patent/CY1118920T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2624846T3 (es) | 2017-07-17 |
| ME02682B (me) | 2017-06-20 |
| CA2869640A1 (en) | 2013-10-31 |
| SI2850075T1 (sl) | 2017-06-30 |
| WO2013163262A1 (en) | 2013-10-31 |
| HUE032173T2 (en) | 2017-09-28 |
| EP2850075B1 (en) | 2017-02-22 |
| CA2869640C (en) | 2018-03-20 |
| DK2850075T3 (en) | 2017-05-22 |
| CN104302639B (zh) | 2017-03-29 |
| CN104302639A (zh) | 2015-01-21 |
| JP6069491B2 (ja) | 2017-02-01 |
| US20130287730A1 (en) | 2013-10-31 |
| CY1118920T1 (el) | 2018-01-10 |
| PT2850075T (pt) | 2017-05-02 |
| EP2850075A1 (en) | 2015-03-25 |
| PL2850075T3 (pl) | 2017-08-31 |
| JP2015514807A (ja) | 2015-05-21 |
| LT2850075T (lt) | 2017-05-10 |
| US9206159B2 (en) | 2015-12-08 |
| RS55864B1 (sr) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| RU2014122340A (ru) | Ингибиторы вируса гепатита с, имеющие жесткую вытянутую цепь и содержащие фрагмент {2-[4-(бифенил-4-ил)-1н-имидазо-2-ил]пирролидин-1-карбонилметил}амина | |
| HRP20241540T1 (hr) | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk | |
| JP2013521279A5 (cg-RX-API-DMAC10.html) | ||
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20160623T1 (hr) | Inhibitori proteinske kinaze | |
| HRP20110428T1 (hr) | Derivati piperidin-amino-benzimidazola kao inhibitori respiratorne sincitijalne virusne replikacije | |
| AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| JP2013514359A5 (cg-RX-API-DMAC10.html) | ||
| BR112015003380A2 (pt) | composto de pirazolopirimidina | |
| HRP20220628T1 (hr) | Postupci i međuprodukti za pripremu lijeka | |
| JP2013529196A5 (cg-RX-API-DMAC10.html) | ||
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| ME02566B (me) | Derivati imidazopiridazina kao modulatori receptora gabaa | |
| HRP20220278T1 (hr) | 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima | |
| JP2016518359A5 (cg-RX-API-DMAC10.html) | ||
| HRP20180483T1 (hr) | Spoj kinolona |